An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remains on the market.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
